Brief: Ionis Partner GSK Says FDA Grants Priority Review, Breakthrough Status to Hepatitis B Drug Bepirovirsen
28/04/2026 08:14
April 28 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS PARTNER GSK ANNOUNCES BEPIROVIRSEN ACCEPTED FOR PRIORITY REVIEW AND GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA AS A POTENTIAL FIRST-IN-CLASS MEDICINE FOR CHRONIC HEPATITIS B IONIS PHARMACEUTICALS INC: PDUFA DATE OF OCTOBER 26, 2026 IONIS PHARMACEUTICALS INC: FDA SETS PDUFA TARGET ACTION DATE FOR BEPIROVIRSEN OF OCTOBER 26, 2026 Source text: ID:nBwbgM6WWa Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors